Relationship between salivary inflammatory mediators and oral dryness during chemotherapy in patients with cancer: a cohort study
Zusammenhang zwischen salivären inflammatorischen Mediatoren und oraler Trockenheit während einer Chemotherapie bei Krebspatient:innen: Kohortenstudie
Supportive Care in Cancer · 2026-06 · 34 (6)
DOI: 10.1007/s00520-026-10796-7 ↗Auf einen Blick
Bei 162 Patient:innen unter Chemotherapie war orale Trockenheit mit TNF-, IL-10-Werten und dem Zeitpunkt der Probenahme nach Chemotherapie assoziiert.
Fragestellung
Besteht bei Krebspatient:innen unter Chemotherapie ein Zusammenhang zwischen salivären inflammatorischen Mediatoren und oraler Trockenheit?
Methode
Prospektive Kohortenstudie an einem Zentrum mit Erwachsenen unter Chemotherapie oder Chemoradiotherapie; Erhebung von 2021 bis 2023; Analyse von Untersaliva und klinischen Daten.
Ergebnisse
56 von 162 Patient:innen (34,6 %) hatten orale Trockenheit. TNF > 4,7 pg/mL war invers assoziiert (OR 0,27; 95 %-KI 0,11–0,69), IL-10 > 2,8 pg/mL positiv assoziiert (OR 3,17; 95 %-KI 1,30–7,75).
Schlussfolgerung der Autor:innen
Saliväre TNF- und IL-10-Spiegel sowie der Zeitpunkt der Probenahme nach Chemotherapie waren mit oraler Trockenheit assoziiert und sprechen für zeitliche Veränderungen salivärer inflammatorischer Mediatoren.
Kernaussagen
- 56 von 162 Patient:innen hatten orale Trockenheit
- TNF > 4,7 pg/mL: OR 0,27 (95 %-KI 0,11–0,69)
- IL-10 > 2,8 pg/mL: OR 3,17 (95 %-KI 1,30–7,75)
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Kohortenstudie in der Zeitschrift Supportive Care in Cancer, online erschienen am 28.05.2026. Verfasst von Anna Kiyomi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. akiyomi@toyaku.ac.jp. Hauptthemen laut MEDLINE: Saliva, Stomatitis, Neoplasms, Inflammation Mediators. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
To evaluate the association between salivary inflammatory mediators and oral dryness during oral mucositis development in patients with cancer undergoing chemotherapy.
Methods
This prospective cohort study (time-stratified sampling) enrolled adult patients undergoing chemotherapy or chemoradiotherapy at Niigata University Medical and Dental Hospital (November 2021–August 2023). Sample size was determined a priori from a pilot study. Oral mucosal status was graded using the World Health Organization oral toxicity scale, and oral moisture was measured (dryness < 28). Unstimulated whole saliva was analyzed for interleukins (IL)-1β, IL-6, IL-8, IL-10, IL-12p70, tumor necrosis factor (TNF), prostaglandin E2, and vascular endothelial growth factor via cytometric bead array and enzyme-linked immunosorbent assay. Clinical data included demographics, treatment, and days post-chemotherapy (0–7, 8–14, ≥ 15). TNF and IL-10 were independently associated with oral dryness; cutoffs were median levels in patients with grade 0 mucositis.
Results
Among 162 patients, 56 (34.6%) had oral dryness. Dryness was associated with higher neutrophil counts (median: 3.23 vs. 3.00 × 10 3 /µL; p = 0.04). C-reactive protein levels increased, and neutrophil counts decreased 8–14 days post-chemotherapy. Multivariate analysis showed that TNF > 4.7 pg/mL was inversely associated (OR = 0.27; 95% CI = 0.11–0.69; p = 0.0058), whereas IL-10 > 2.8 pg/mL was positively associated (OR = 3.17; 95% CI = 1.30–7.75; p = 0.011) with dryness. Sampling at 8–14 days post-chemotherapy predicted dryness (OR = 5.16; 95% CI = 1.32–20.09; p = 0.018).
Conclusions
Salivary TNF and IL-10 levels and sampling timing after CT were associated with oral dryness, suggesting temporal changes in salivary inflammatory mediators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. akiyomi@toyaku.ac.jp.
- Laboratory of Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan. yoshida@toyaku.ac.jp.
- Laboratory of Drug Safety and Risk Management, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
- Oral Management Clinic for Medical Cooperation, Niigata University Medical and Dental Hospital, Niigata, Japan.
- Division of Hospital Pharmacy, Niigata University Medical and Dental Hospital, Niigata, Japan.
- Division of Oral and Maxillofacial Surgery, Faculty of Dentistry & Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Zitieren
APA
Kiyomi, A., Yoshida, K., Okamoto, N., Kurokawa, A., Saito, C., Kanemaru, H., Tomihara, K., Ohuchi, A., & Sugiura, M. (2026). Relationship between salivary inflammatory mediators and oral dryness during chemotherapy in patients with cancer: a cohort study. Supportive Care in Cancer, 34(6). https://doi.org/10.1007/s00520-026-10796-7
Vancouver
Kiyomi A, Yoshida K, Okamoto N, Kurokawa A, Saito C, Kanemaru H, et al. Relationship between salivary inflammatory mediators and oral dryness during chemotherapy in patients with cancer: a cohort study. Supportive Care in Cancer. 2026;34(6). doi:10.1007/s00520-026-10796-7
BibTeX
@article{Kiyomi2026,
author = {Kiyomi, Anna and Yoshida, Kensuke and Okamoto, Nana and Kurokawa, Akira and Saito, Chie and Kanemaru, Hiroko and Tomihara, Kei and Ohuchi, Akitsugu and Sugiura, Munetoshi},
title = {Relationship between salivary inflammatory mediators and oral dryness during chemotherapy in patients with cancer: a cohort study},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {6},
doi = {10.1007/s00520-026-10796-7}
}
EUVIMED